African Journal of
Biotechnology

  • Abbreviation: Afr. J. Biotechnol.
  • Language: English
  • ISSN: 1684-5315
  • DOI: 10.5897/AJB
  • Start Year: 2002
  • Published Articles: 12200

Full Length Research Paper

Multidrug-resistant hepatocellular carcinoma cells are enriched for CD133+ subpopulation through activation of TGF-β1/Smad3 pathway

Wei Yan
  • Wei Yan
  • Department of General Surgery, Zhongshan Hospital, Xiamen University,Xiamen 361004, People’s Republic of China; Department of Surgery, College of Medicine, Xiamen University, Xiamen 361005, People’s Republic of China.
  • Google Scholar
Fen Lin
  • Fen Lin
  • Department of General Surgery, Zhongshan Hospital, Xiamen University,Xiamen 361004, People’s Republic of China; Department of Surgery, College of Medicine, Xiamen University, Xiamen 361005, People’s Republic of China.
  • Google Scholar
Ting Wen
  • Ting Wen
  • Department of General Surgery, Zhongshan Hospital, Xiamen University,Xiamen 361004, People’s Republic of China; Department of Surgery, College of Medicine, Xiamen University, Xiamen 361005, People’s Republic of China.
  • Google Scholar
Zhongcai Liu
  • Zhongcai Liu
  • Department of General Surgery, Zhongshan Hospital, Xiamen University,Xiamen 361004, People’s Republic of China; Department of Surgery, College of Medicine, Xiamen University, Xiamen 361005, People’s Republic of China.
  • Google Scholar
Suqiong Lin
  • Suqiong Lin
  • Department of General Surgery, Zhongshan Hospital, Xiamen University,Xiamen 361004, People’s Republic of China; Department of Surgery, College of Medicine, Xiamen University, Xiamen 361005, People’s Republic of China.
  • Google Scholar
Guoyang Wu*
  • Guoyang Wu*
  • Department of General Surgery, Zhongshan Hospital, Xiamen University,Xiamen 361004, People’s Republic of China.
  • Google Scholar


  •  Received: 23 October 2011
  •  Accepted: 28 July 2014
  •  Published: 20 August 2014

References

Abou-Shady M, Baer HU, Friess H, Berberat P, Zimmermann A, Graber H, Gold LI, Korc M, Buchler MW (1999). Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am. J. Surg. 177(3):209-215.
Crossref
 
Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabro E, Pastorino U, Sozzi G (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA. 106(38):16281-16286.
Crossref
 
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006). Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66(19):9339-9344.
Crossref
 
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65(23):10946-10951.
Crossref
 
Dean M, Fojo T, Bates S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer. 5(4):275-284.
Crossref
 
Ding W, Mouzaki M, You H, Laird JC, Mato J, Lu SC, Rountree CB (2009). CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology 49(4):1277-1286.
Crossref
 
Du Z, Qin R, Wei C, Wang M, Shi C, Tian R, Peng C (2011). Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig. Dis. Sci. 56(3):741-750.
Crossref
 
Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, Clarke MF, Hoey T, Lewicki J, Gurney AL (2008). Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One. 3(6):e2428.
Crossref
 
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 127(12):2893-2917.
Crossref
 
Ikushima H, Miyazono K (2010). TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer. 10(6):415-424.
Crossref
 
Jin X, Mei H, Li X, Ma Y, Zeng AH, Wang Y, Lu X, Chu F, Wu Q, Zhu J (2010). Apoptosis-inducing activity of the antimicrobial peptide cecropin of Musca domestica in human hepatocellular carcinoma cell line BEL-7402 and the possible mechanism. Acta Biochim Biophys Sin (Shanghai). 42(4):259-265.
Crossref
 
Kamohara Y, Haraguchi N, Mimori K, Tanaka F, Inoue H, Mori M, Kanematsu T (2008). The search for cancer stem cells in hepatocellular carcinoma. Surgery. 144(2):119-124.
Crossref
 
Kelly RJ, Morris JC (2010). Transforming growth factor-beta: a target for cancer therapy. J. Immunotoxicol. 7(1):15-26.
Crossref
 
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nat. 367(6464):645-648.
Crossref
 
Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE (2008). Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One. 3(8):e3077.
Crossref
 
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007). Identification of pancreatic cancer stem cells. Cancer Res. 67(3):1030-1037.
Crossref
 
Ma L, Lai D, Liu T, Cheng W, Guo L (2010). Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai). 42(9):593-602.
Crossref
 
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY (2007). Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 132(7):2542-2556.
Crossref
 
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133(4):704-715.
Crossref
 
Matsuzaki K (2009). Modulation of TGF-beta signaling during progression of chronic liver diseases. Front Biosci. 14:2923-2934.
Crossref
 
Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sakitani K, Yamashiki N, Seki T, Saito H, Nishizawa M, Fujisawa J, Inoue K (2000). Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res. 60(5): 1394-1402.
Pubmed
 
Nishimura T, Azuma T, Yokoyama A, Ochiai H, Saito H, Hibi T (2009). New mechanism of transforming growth factor-beta signaling in hepatoma: Dramatic up-regulation of tumor initiating cells and epidermal growth factor receptor expression. Hepatol. Res. 39(5):501-509.
Crossref
 
Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG (2006). Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 25(12):1696-1708.
Crossref
 
Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG (2005). Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65(13):5506-5511.
Crossref
 
Reya T, Morrison SJ, Clarke MF, Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nat. 414(6859):105-111.
Crossref
 
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007). Identification and expansion of human colon-cancer-initiating cells. Nat. 445(7123):111-115.
Crossref
 
Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH (2008). Identification of cells initiating human melanomas. Nature. 451(7176):345-349.
Crossref
 
Singh A, Settleman J (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 29(34):4741-4751.
Crossref
 
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res. 63(18):5821-5828.
Pubmed
 
Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H (2006). Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 351(4):820-824.
Crossref
 
Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, Ressom HW, Rashid A, He AR, Mendelson JS, Jessup JM, Shetty K, Zasloff M, Mishra B, Reddy EP, Johnson L, Mishra L (2008). Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc. Natl. Acad. Sci. USA. 105(7):2445-2450.
Crossref
 
Terris B, Cavard C, Perret C (2010). EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J. Hepatol. 52(2):280-281.
Crossref
 
Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A (2010). Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J. Clin. Oncol. 28(25):3994-4005.
Crossref
 
Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P (2008). Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann. Surg. Oncol. 15(4):1008-1014.
Crossref
 
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW (2009). EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterol. 136(3):1012-1024.
Crossref
 
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST (2008a). Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 13(2):153-166.
Crossref
 
Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, Li ML, Tam KH, Lam CT, Poon RT, Fan ST (2008b). Identification of local and circulating cancer stem cells in human liver cancer. Hepatol. 47(3):919-928.
Crossref
 
Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J (2007). CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer. 120(7):1444-1450.
Crossref
 
You H, Ding W, Rountree CB (2010). Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatol. 51(5):1635-1644.
Crossref
 
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E (2007). let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell 131(6):1109-1123.
Crossref
 
Zhang L, Jia X, Peng X, Ou Q, Zhang Z, Qiu C, Yao Y, Shen F, Yang H, Ma F, Wang J, Yuan Z (2010a). Development and validation of a liquid chromatography-mass spectrometry metabonomic platform in human plasma of liver failure caused by hepatitis B virus. Acta Biochim Biophys Sin (Shanghai). 42(10):688-698.
Crossref
 
Zhang X, Yashiro M, Qiu H, Nishii T, Matsuzaki T, Hirakawa K (2010b). Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res. 30(3):915-921.
Pumed
 
Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB (2009). Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8(10):806-823.
Crossref
 
Zhou Y, Ling XL, Li SW, Li XQ, Yan B (2010). Establishment of a human hepatoma multidrug resistant cell line in vitro. World J. Gastroenterol. 16(18):2291-2297.
Crossref
 
Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J (2010). Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer. 126(9):2067-2078.
Pubmed
 
Zou GM (2010a). Liver cancer stem cells as an important target in liver cancer therapies. Anticancer Agents Med Chem. 10(2):172-175.
Crossref
 
Zou GM (2010b). Liver Cancer Stem Cells as an Important Target in Liver Cancer Therapies. Anticancer Agents Med Chem. 10(2):172-175.
Crossref